Trial · NCT04543409
Results by group228
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 228
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Percentage of Patients With a Histologic Response, Defined as a Peak Esophageal Intraepithelial Eosinophil Count ≤ 6 Eos/Hpf. | Benralizumab | Week 24 | 87.4 | 95% Confidence Interval 80.97 to 93.79 | Percentage of Participants |
| Percentage of Patients With a Histologic Response, Defined as a Peak Esophageal Intraepithelial Eosinophil Count ≤ 6 Eos/Hpf. | Placebo | Week 24 | 6.5 | 95% Confidence Interval 1.86 to 11.23 | Percentage of Participants |
| Percentage of Patients With a Histologic Response, Defined as a Peak Esophageal Intraepithelial Eosinophil Count ≤ 6 Eos/Hpf. | Benralizumab | Week 52 | 82.6 | 95% Confidence Interval 71.66 to 93.56 | Percentage of Participants |
| Percentage of Patients With a Histologic Response, Defined as a Peak Esophageal Intraepithelial Eosinophil Count ≤ 6 Eos/Hpf. | Placebo | Week 52 | 89.4 | 95% Confidence Interval 80.55 to 98.18 | Percentage of Participants |
| Changes From Baseline in Dysphagia Symptom Questionnaire (DSQ) | Benralizumab | Week 24 | -12.102 | 95% Confidence Interval -16.05 to -8.15 | Score |
| Changes From Baseline in Dysphagia Symptom Questionnaire (DSQ) | Placebo | Week 24 | -15.101 | 95% Confidence Interval -19.02 to -11.19 | Score |
| Changes From Baseline in Dysphagia Symptom Questionnaire (DSQ) | Benralizumab | Week 52 | -19.409 | 95% Confidence Interval -25.65 to -13.17 | Score |
| Changes From Baseline in Dysphagia Symptom Questionnaire (DSQ) | Placebo | Week 52 | -19.806 | 95% Confidence Interval -25.70 to -13.91 | Score |
| Percent Change From Baseline in Tissue Eosinophils | Benralizumab | Week 24 | -94.8 | 95% Confidence Interval -100.00 to -82.45 | Percentage of change |
| Percent Change From Baseline in Tissue Eosinophils | Placebo | Week 24 | 1.4 | 95% Confidence Interval -11.75 to 14.60 | Percentage of change |
| Percent Change From Baseline in Tissue Eosinophils | Benralizumab | Week 52 | -85.0 | 95% Confidence Interval -100.00 to -62.50 | Percentage of change |
| Percent Change From Baseline in Tissue Eosinophils | Placebo | Week 52 | -88.6 | 95% Confidence Interval -100.00 to -73.67 | Percentage of change |
| Change From Baseline in Eosinophilic Esophagitis-Histology Scoring System (EoE-HSS) Total Grade Score at Week 24 | Benralizumab | -0.264 | 95% Confidence Interval -0.297 to -0.232 | Grade Score Ratio Change | |
| Change From Baseline in Eosinophilic Esophagitis-Histology Scoring System (EoE-HSS) Total Grade Score at Week 24 | Placebo | -0.089 | 95% Confidence Interval -0.122 to -0.056 | Grade Score Ratio Change | |
| Change From Baseline in Eosinophilic Esophagitis-Histology Scoring System (EoE-HSS) Total Stage Score at Week 24 | Benralizumab | -0.199 | 95% Confidence Interval -0.228 to -0.169 | Grade Score Ratio Change | |
| Change From Baseline in Eosinophilic Esophagitis-Histology Scoring System (EoE-HSS) Total Stage Score at Week 24 | Placebo | -0.077 | 95% Confidence Interval -0.107 to -0.046 | Grade Score Ratio Change | |
| Changes From Baseline in Centrally-read Endoscopic Reference Score (EREFS) | Benralizumab | Week 24 | -0.5 | 95% Confidence Interval -0.91 to -0.10 | Score |
| Changes From Baseline in Centrally-read Endoscopic Reference Score (EREFS) | Placebo | Week 24 | -0.4 | 95% Confidence Interval -0.85 to -0.01 | Score |
| Changes From Baseline in Centrally-read Endoscopic Reference Score (EREFS) | Benralizumab | Week 52 | -0.3 | 95% Confidence Interval -0.9 to 0.32 | Score |
| Changes From Baseline in Centrally-read Endoscopic Reference Score (EREFS) | Placebo | Week 52 | -0.7 | 95% Confidence Interval -1.35 to -0.09 | Score |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT04543409/results